Literature DB >> 21205134

Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.

Arun J Sanyal1.   

Abstract

Hepatitis C is a common cause of chronic viral infection of the liver. It is associated with insulin resistance and the development of type 2 diabetes mellitus. It is also associated with the development of hepatic steatosis. The presence of hepatic steatosis is associated with an increased risk of having hepatic fibrosis. This is also associated with the severity of insulin resistance. These findings are specifically germane for those with genotype1 infection. Genotype 3 infection independently causes steatosis and successful treatment of the virus is followed by resolution of steatosis. In genotype 1 infection, the presence of hepatic steatosis is also a risk factor for failure to respond to pegylated interferon and ribavirin therapy. Unfortunately efforts to treat insulin resistance prior to antiviral therapy have not been very successful. Newer efforts focused on the role of specific micro RNAs in mediating the metabolic effects of hepatitis C virus infection may provide to ameliorate the metabolic risks of HCV infection.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205134     DOI: 10.1111/j.1478-3231.2010.02397.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis.

Authors:  Charles Harris; Eva Herker; Robert V Farese; Melanie Ott
Journal:  J Biol Chem       Date:  2011-10-07       Impact factor: 5.157

Review 2.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

Review 3.  Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.

Authors:  Ludovico Abenavoli; Mario Masarone; Valentina Peta; Natasa Milic; Nazarii Kobyliak; Samir Rouabhia; Marcello Persico
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 4.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Authors:  Iliana Doycheva; Niraj Patel; Michael Peterson; Rohit Loomba
Journal:  J Diabetes Complications       Date:  2013-01-09       Impact factor: 2.852

5.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

6.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

7.  Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression.

Authors:  Yutaka Amako; Tsubasa Munakata; Michinori Kohara; Aleem Siddiqui; Chris Peers; Mark Harris
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

8.  Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.

Authors:  Claus Niederau; Stefan Mauss; Andreas Schober; Albrecht Stoehr; Tim Zimmermann; Michael Waizmann; Gero Moog; Stefan Pape; Bernd Weber; Konrad Isernhagen; Petra Sandow; Bernd Bokemeyer; Ulrich Alshuth; Hermann Steffens; Dietrich Hüppe
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

9.  Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture.

Authors:  Feyza Gunduz; Fatma M Aboulnasr; Partha K Chandra; Sidhartha Hazari; Bret Poat; Darren P Baker; Luis A Balart; Srikanta Dash
Journal:  Virol J       Date:  2012-08-03       Impact factor: 4.099

10.  Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus.

Authors:  Shao Qing; Dong Ji; Bing Li; Fan Li; Yudong Wang; Xioaxia Niu; Binfang Ling; Yuhua Meng; George Lau; Guofeng Chen
Journal:  Ann Saudi Med       Date:  2015 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.